Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response
about
Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunityHow Chemotherapy Increases the Risk of Systemic Candidiasis in Cancer Patients: Current Paradigm and Future DirectionsTargeting the indoleamine 2,3-dioxygenase pathway in cancerRelevance of tumor-infiltrating lymphocytes in breast cancerVaccines for pancreatic cancerAllogeneic tumor cell vaccines: the promise and limitations in clinical trialsTumor antigen-specific monoclonal antibodies and induction of T-cell immunityImmunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapyThe interplay of immunotherapy and chemotherapy: harnessing potential synergiesTrafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cellsImmunosuppressive strategies that are mediated by tumor cellsRandomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccineIn vivo imaging of T cell delivery to tumors after adoptive transfer therapy.IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes.Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinomaLinear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunityCyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinomaAn anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in miceStromal reengineering to treat pancreas cancerImmunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulationLow-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.Features of responding T cells in cancer and chronic infection.Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effectsCD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphomaChemoimmunotherapy.Up-regulation of Th17 cells may underlie inhibition of Treg development caused by immunization with activated syngeneic T cells.Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization.Neoadjuvant anti-tumor vaccination prior to surgery enhances survival.Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapyImmune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.
P2860
Q24610550-CC9AA5B5-5633-4115-980F-150E89851B5CQ26771113-CE308363-8EC8-475A-A8AE-2B5D7484937BQ26775471-0C087F95-682E-4CDE-BFDD-C9B912FB56A5Q26795598-AF776391-D77D-4C82-826F-A4D2B29A1D65Q26825850-60CFCD22-B0D2-43A2-8B4A-C98AF696EB2BQ26852333-7AD635E1-80CF-43E8-A03D-D631E63D1646Q27009908-345BEE9F-11D4-4054-A132-D88678C036CAQ27027093-AB7FB100-B3C5-4E6E-B7D4-E33D28018251Q28081893-7F3AC4F6-C3E4-4F7A-BF08-70FACE4479D4Q28732041-83563FFF-8D0D-4310-88CB-0B406C8D26CCQ29636247-18BCDB3C-87C8-4DE2-B450-D7841A6BD140Q30425914-F954A133-C65C-49DF-BB9A-58A9945F41DCQ30479855-AE3B36ED-2BAB-4B8D-8381-76155D227536Q30481064-57B6E9DF-C28F-47E1-B174-964EC97714A9Q33299427-FA1B8C4A-6B60-40E9-9DBD-5F1153977DDFQ33502208-7EA65CC2-5436-4EDF-BA61-B5D3D11AF1DDQ33579629-E60E5DCB-9544-44F7-AA23-5C35AA8A5B24Q33614657-BAA9F314-FE6B-453B-8C91-FA5AB7FBFF99Q33653210-1C26EBE7-FDEC-4F38-9C03-DBAB205EBA08Q33738279-62DEE8A5-3192-44A3-9743-0DE4C65A2941Q33773435-59F17FE0-109D-4D9B-964D-7AE1AD9E9450Q33823499-A3C0C8A5-D118-479D-A48E-7A5FF816F789Q33827708-4DBF62F8-B5A3-45EB-8A98-B83DAA6747B4Q33848077-3034EBC2-5FF9-4DEB-B210-28D7CC08F7F4Q33871059-6B2A46B3-C48E-448E-85D7-4F2B12B5A307Q33887648-E84A6B1E-67CE-4597-AEA9-5DFD11C14DF2Q33941340-35CB0CBA-F79F-4B4B-B743-D9E0E14F484BQ34013869-E750F41D-CCAC-4DCD-9AAC-94007F52095BQ34014497-F737DDFF-842C-4E53-B2E7-F1F3CA5FEF11Q34058792-34D76D32-F2D8-475F-A2DA-854BE6492C7EQ34075574-883B5BF4-EDFB-4778-B318-8825C278CC45Q34082964-F28CB954-BB07-4F87-B470-A7BFFBA7BD70Q34145877-2991729F-AAD5-4508-BB40-08ED372A0640Q34187201-0A2E67A9-AFD7-4E2A-ABB5-9802B240C8ACQ34315863-96E399A6-D96E-4310-BD68-3E12521E3ADCQ34330865-91C3DB1A-DF63-44AB-A6EB-F655D0D97185Q34412289-E8B2376F-104A-4FB3-879E-50C8E3E0361DQ34477650-9154B5D1-CB5F-44FD-96AD-1C761D56F41CQ34556927-033364B0-5489-4C06-B30E-CD6DAC02E918Q34557233-1C046DB8-DF69-4805-ADF4-72DCE83ED310
P2860
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Recruitment of latent pools of ...... the antitumor immune response
@ast
Recruitment of latent pools of ...... the antitumor immune response
@en
type
label
Recruitment of latent pools of ...... the antitumor immune response
@ast
Recruitment of latent pools of ...... the antitumor immune response
@en
prefLabel
Recruitment of latent pools of ...... the antitumor immune response
@ast
Recruitment of latent pools of ...... the antitumor immune response
@en
P2093
P2860
P356
P1476
Recruitment of latent pools of ...... the antitumor immune response
@en
P2093
Anne M Ercolini
Brian H Ladle
Elizabeth A Manning
Jean-Pascal H Machiels
Joan G Bieler
Leisha A Emens
Lukas W Pfannenstiel
R Todd Reilly
Todd D Armstrong
P2860
P304
P356
10.1084/JEM.20042167
P407
P577
2005-05-09T00:00:00Z